Results 211 to 220 of about 80,532 (301)

The status of cell and gene therapy education in medical schools—An international survey

Transfusion, EarlyView.
Abstract Introduction Cell and gene therapy (CGT) has emerged as a distinct medical field with more than 50 “Food and Drug Administration (FDA)”‐approved products treating conditions from leukemia to sickle cell disease. Despite this therapeutic revolution and the field's inherent complexity, the status of CGT education in medical schools remains ...
Edina A. Wappler‐Guzzetta, Alexandra M. Tabacu, Elena Nedelcu   +2 more
wiley   +1 more source

Nanobody-Based CAR NK Cells for Possible Immunotherapy of Mesothelin⁺ Tumors. [PDF]

Immune Netw
Jung D, Choi E, Jeoung YH, Lee J, Gong EY, Jo SG, Noh K, Ha K, Wee G, Kim H, Jung J, Kim S.   +11 more
europepmc   +1 more source

Peripheral T‐Cell Lymphomas in Southern Taiwan: Epidemiology, Treatment Patterns, and Long‐Term Outcomes

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Peripheral T‐cell lymphomas (PTCLs) are heterogeneous neoplasms with poor prognosis and marked geographic variation. Data from Taiwan remain limited. We conducted a 15‐year retrospective cohort study of 249 patients diagnosed with PTCL at two major centers in southern Taiwan between 2010 and 2024 to characterize regional epidemiology, real ...
Bo‐Yu Huang, Li‐Chang Chang, Sheng‐Yen Hsiao, Ya‐Ping Chen, Sin‐Syue Li, Pei‐An Fu, Chen Chang, Kung‐Chao Chang, Tsai‐Yun Chen, Ya‐Ting Hsu   +9 more
wiley   +1 more source

CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy. [PDF]

Front Immunol
Dos Reis FD, Saidani Y, Martín-Rubio P, Sanz-Pamplona R, Stojanovic A, Correia MP.   +5 more
europepmc   +1 more source

Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oxidative stress is involved in several key processes in cancer, including redox regulation, DNA damage, post‐translational modifications, transcriptional regulation, epigenetic modifications, metabolic reprogramming, cell death, and immune modulation. These mechanisms collectively influence tumor progression, immune evasion, and therapeutic responses,
Zhen Wang, Bowen Li, Pan Tang, Fanchen Yan, Shuxin Wang, Guiying Leng, Panduo Dawa, Yuansi Chen, Yihan Guo, Pan Yang, Yi Li, Siyu Liu, Erdan Dong, Siyuan Qin, Zhoufeng Wang   +14 more
wiley   +1 more source

Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells. [PDF]

Front Immunol
Guo JH, Afzal A, Ahmad S, Saeed G, Rehman A, Saddozai UAK, Liu L, Guo SH, Ji XY, Khawar MB.   +9 more
europepmc   +1 more source

Herbarium specimens reveal drivers of Arctic shrub growth

New Phytologist, EarlyView.
Natalie Iwanycki Ahlstrand, Zoe A. Panchen, Anne D. Bjorkman, James D. M. Speed   +3 more
wiley   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T. [PDF]

J Immunother Cancer
Wang N, Liu L, Zhang L, Li J, Wan Y, Li X, Chen X, Yin Z, Zhang A, Zhang X, Chen Y, Hu T, Zhang Y, Liu F, Zhu X, Yang W.   +15 more
europepmc   +1 more source

Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy

European Journal of Haematology, Volume 116, Issue 6, Page 771-784, June 2026.
ABSTRACT Primary refractory Diffuse Large B‐Cell Lymphoma is associated with poor outcomes and limited responsiveness to conventional salvage therapies. Although CAR T‐cell therapy represents the standard of care in this setting, a substantial proportion of patients cannot receive it despite meeting disease‐related criteria. In this review, “unsuitable”
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source